A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions

Inclusion Criteria: * Healthy adult male or female volunteers, 18-55 years of age. * Weighing at least 60 kg for males and 52 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983). * Medically healthy subjects with clinically normal laboratory profiles, vital signs and ECGs. * Females of childbearing potential were either sexually inactive (abstinent) for 14 days prior to the first dose, throughout the study and for 6 days following the last dose or were using one of the following acceptable birth control methods: * surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum; * IUD in place for at least 3 months; * barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose, throughout the study and for 6 days following the last dose; * surgical sterilization of the partner (vasectomy for 6 months minimum); * hormonal contraceptives for at least 3 months prior to the first dose of the study and up to 6 days following the last dose. Other birth control methods may have been deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years were eligible. * Gave voluntary written informed consent to participate in the study. Exclusion Criteria: * History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. * In addition, history or presence of: * alcoholism or drug abuse within the past year; * hypersensitivity or idiosyncratic reaction to venlafaxine or other selective serotonin and norepinephrine reuptake inhibitors; * glaucoma. * Female subjects who were pregnant or lactating. * Subjects who tested positive at screening for HIV, HbsAg or HCV. * Subjects who received monoamine oxidase (MAO) inhibitors within 28 days prior to dosing. * Subjects who used any drugs or substances known to be strong inhibitors of CYP enzymes (formerly known as P450 enzymes) within 10 days prior to the first dose. * Subjects who used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as P450 enzymes) within 28 days prior to the first dose. * Subjects who donated 50 to 499 mL of blood within 30 days and more than 499 mL within 56 days prior to the first dose. * Subjects who, through completion of the study, would have donated in excess of: * 500 mL of blood in 14 days; or * 1500 mL of blood in 180 days; or * 2500 mL of blood in 1 year. * Subjects whose PR interval is \>200 msec at screening and prior to dosing. * Subjects whose QTc interval is \>450 msec at screening and prior to dosing. * Subjects who completed another clinical trial within 28 days prior to the first dose. * Subjects who were on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.